SCHEMBL26416614

SCHEMBL26416614

CCc1cc(Oc2c(C(=O)N[C@@H](C)c3ccc(C(=O)OC)cc3)c(C)nn2C)ccc1F

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 8/20 0.57
PTGER2 P43116 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
LMNA P02545 3/20 0.39
ALDH1A1 P00352 1/20 0.39
PHGDH O43175 3/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
PPARG P37231 2/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
PPARD Q03181 1/20 0.37
PPARA Q07869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26416612 0.92 PTGER4 (0.68) PTGER4PTGER2CYP1A2CYP3A4CYP2C9
SCHEMBL30331297 0.90 PTGER4 (0.63) PTGER4PTGER2LMNAALDH1A1PHGDH
SCHEMBL26418590 0.90 PTGER4 (0.63) PTGER4PTGER2LMNAALDH1A1PHGDH
SCHEMBL24861962 0.90 PTGER4 (0.63) PTGER4PTGER2LMNAALDH1A1PHGDH
SCHEMBL24861965 0.86 PTGER4 (0.64) PTGER4PTGER2LMNAALDH1A1PHGDH
SCHEMBL28708481 0.86 PTGER4 (0.64) PTGER4PTGER2LMNAALDH1A1PHGDH
SCHEMBL24861737 0.83 PTGER4 (0.63) PTGER4PTGER2LMNAALDH1A1PHGDH
SCHEMBL24861736 0.83 PTGER4 (0.63) PTGER4PTGER2LMNAALDH1A1PHGDH
SCHEMBL30331227 0.83 PTGER4 (0.63) PTGER4PTGER2LMNAALDH1A1PHGDH
SCHEMBL881393 0.83 PTGER4 (0.72) PTGER4PTGER2CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230125494-A1 SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230125494-A1 SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION PTGER4, PTGER3, PTGER2 PTGER4 1/4885PTGER2 3/4885CYP1A2 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.